{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:32:07Z","timestamp":1770708727450,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the efficacy of ixekizumab (IXE), a monoclonal antibody selectively targeting interleukin-17A, in patients with inadequate response to one or two TNF inhibitors (TNFi).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A phase 3 study (SPIRIT-P2; NCT02349295) randomized patients with PsA with inadequate response or intolerance to one or two TNFi to receive 80-mg IXE every 2\u2009weeks (n\u2009=\u2009123) or every 4\u2009weeks (n\u2009=\u2009122) after a 160-mg starting dose or placebo (PBO; n\u2009=\u2009118) through week 24. This post hoc analysis used data from inadequate responders to one or two TNFi, measuring the percentage achieving: \u226550% improvement in ACR response criteria (ACR50) and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 100), ACR50, improvement in HAQ-Disability Index (HAQ-DI) \u22650.35, minimal disease activity (MDA), European League Against Rheumatism (EULAR) Good Response Criteria [improvement in Disease Activity Score 28\u2009CRP (DAS28-CRP) &amp;gt;1.2], and Disease Activity in PsA (DAPSA) \u226414.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were no significant differences in baseline characteristics between inadequate responders to one and two TNFi. At week 24, significantly more patients irrespective of previous TNFi experience receiving IXE than PBO achieved ACR50, HAQ-DI \u22650.35 improvement, MDA, EULAR good response, and DAPSA \u226414, and significantly more patients with inadequate response to one TNFi receiving IXE than PBO achieved ACR50 and PASI 100. Improvement persisted in all measures through week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IXE improved the signs and symptoms of PsA in a population of difficult-to-treat patients with inadequate response to one or two TNFi.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa824","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T04:12:07Z","timestamp":1606363927000},"page":"4367-4372","source":"Crossref","is-referenced-by-count":4,"title":["Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors"],"prefix":"10.1093","volume":"60","author":[{"given":"Bruce","family":"Kirkham","sequence":"first","affiliation":[{"name":"Guy\u2019s & St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sesin","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, Miami Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda M.","family":"Gellett","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubrey T.","family":"Sprabery","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Turkiewicz","sequence":"additional","affiliation":[{"name":"Rheumatology Associates, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"2021090119420315800_keaa824-B1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11926-013-0316-4","article-title":"Psoriatic arthritis: phenotypic variance and nosology","volume":"15","author":"Eder","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2021090119420315800_keaa824-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021090119420315800_keaa824-B3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021090119420315800_keaa824-B4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","article-title":"Psoriatic arthritis","volume":"22","author":"Gladman","year":"2009","journal-title":"Dermatol Ther"},{"key":"2021090119420315800_keaa824-B5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","article-title":"Switching between biological treatments in psoriatic arthritis: a review of the evidence","volume":"17","author":"Costa","year":"2017","journal-title":"Drugs R D"},{"key":"2021090119420315800_keaa824-B6","volume-title":"Ixekizumab [prescribing information]","year":"2017"},{"key":"2021090119420315800_keaa824-B7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021090119420315800_keaa824-B8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"2021090119420315800_keaa824-B9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"2021090119420315800_keaa824-B10","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021090119420315800_keaa824-B11","doi-asserted-by":"crossref","first-page":"e000880","DOI":"10.1136\/rmdopen-2018-000880","article-title":"Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona Registry","volume":"5","author":"Mease","year":"2019","journal-title":"RMD Open"},{"key":"2021090119420315800_keaa824-B12","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4367\/40214888\/keaa824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4367\/40214888\/keaa824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:42:45Z","timestamp":1630525365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/9\/4367\/6104519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,1,20]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa824","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,1,20]]}}}